A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 5, 2020

Primary Completion Date

March 8, 2021

Study Completion Date

March 8, 2021

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG

AD-214-02

1 tablet administered before the breakfast during 7 days

DRUG

Rabeprazole

1 tablet administered before the breakfast during 7 days

Trial Locations (1)

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Addpharma Inc.

INDUSTRY

NCT04622358 - A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole | Biotech Hunter | Biotech Hunter